Idorsia Ltd Market Cap ($1.03 Billion)
Market Cap & Net Worth: Idorsia Ltd (IDIA)
Idorsia Ltd market cap. Idorsia Ltd (SW:IDIA) has a market capitalization of $1.03 Billion (CHF814.02 Million) as of October 30, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #8496 globally and #121 in its home market, demonstrating a 7.41% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Idorsia Ltd's stock price CHF4.58 by its total outstanding shares 253983453 (253.98 Million).
Idorsia Ltd Market Cap History (2017–2026)
Idorsia Ltd market cap history from 2017 to 2026. Data shows change from $8.17 Billion to $1.47 Billion (-10.99% CAGR). Check IDIA stock price for real-time trading data and today's change.
Idorsia Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Idorsia Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash flow conversion of Idorsia Ltd for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
6.18x
Idorsia Ltd's market cap is 6.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $8.17 Billion | $158.09 Million | -$14.27 Million | 51.69x | N/A |
| 2018 | $5.21 Billion | $60.62 Million | -$386.39 Million | 85.92x | N/A |
| 2019 | $9.61 Billion | $23.82 Million | -$494.65 Million | 403.62x | N/A |
| 2020 | $8.19 Billion | $71.76 Million | -$445.12 Million | 114.20x | N/A |
| 2021 | $5.99 Billion | $35.35 Million | -$634.60 Million | 169.32x | N/A |
| 2022 | $4.31 Billion | $97.10 Million | -$827.90 Million | 44.38x | N/A |
| 2023 | $678.81 Million | $152.39 Million | -$297.92 Million | 4.45x | N/A |
| 2024 | $263.95 Million | $112.51 Million | -$263.76 Million | 2.35x | N/A |
| 2025 | $1.37 Billion | $221.00 Million | -$112.00 Million | 6.18x | N/A |
Competitor Companies of IDIA by Market Capitalization
Companies near Idorsia Ltd in the global market cap rankings as of October 30, 2026. See Idorsia Ltd (IDIA) balance sheet quality index to understand what proportion of total assets are financed by equity.
Key companies related to Idorsia Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Idorsia Ltd (2017–2026)
Market capitalization of Idorsia Ltd from 2017 to today. Between 2017 and today, Idorsia Ltd's market cap moved from $8.17 Billion to $ 1.47 Billion, with a yearly change of -10.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF1.47 Billion | +7.69% |
| 2025 | CHF1.37 Billion | +417.64% |
| 2024 | CHF263.95 Million | -61.12% |
| 2023 | CHF678.81 Million | -84.25% |
| 2022 | CHF4.31 Billion | -28.00% |
| 2021 | CHF5.99 Billion | -26.96% |
| 2020 | CHF8.19 Billion | -14.76% |
| 2019 | CHF9.61 Billion | +84.59% |
| 2018 | CHF5.21 Billion | -36.27% |
| 2017 | CHF8.17 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Idorsia Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.03 Billion USD |
| MoneyControl | $1.03 Billion USD |
| MarketWatch | $1.03 Billion USD |
| marketcap.company | $1.03 Billion USD |
| Reuters | $1.03 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more